JP2014523878A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523878A5
JP2014523878A5 JP2014515985A JP2014515985A JP2014523878A5 JP 2014523878 A5 JP2014523878 A5 JP 2014523878A5 JP 2014515985 A JP2014515985 A JP 2014515985A JP 2014515985 A JP2014515985 A JP 2014515985A JP 2014523878 A5 JP2014523878 A5 JP 2014523878A5
Authority
JP
Japan
Prior art keywords
hdv
immunotherapeutic composition
seq
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014515985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014523878A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/042426 external-priority patent/WO2012174220A1/en
Publication of JP2014523878A publication Critical patent/JP2014523878A/ja
Publication of JP2014523878A5 publication Critical patent/JP2014523878A5/ja
Pending legal-status Critical Current

Links

JP2014515985A 2011-06-14 2012-06-14 D型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法 Pending JP2014523878A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161497039P 2011-06-14 2011-06-14
US61/497,039 2011-06-14
PCT/US2012/042426 WO2012174220A1 (en) 2011-06-14 2012-06-14 Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection

Publications (2)

Publication Number Publication Date
JP2014523878A JP2014523878A (ja) 2014-09-18
JP2014523878A5 true JP2014523878A5 (enExample) 2015-07-23

Family

ID=47357462

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014515985A Pending JP2014523878A (ja) 2011-06-14 2012-06-14 D型肝炎ウイルス感染の治療又は予防のための酵母ベースの組成物及び方法

Country Status (12)

Country Link
US (2) US9579377B2 (enExample)
EP (1) EP2720716B1 (enExample)
JP (1) JP2014523878A (enExample)
CN (1) CN103732250A (enExample)
AU (1) AU2012271625B2 (enExample)
BR (1) BR112013032381B1 (enExample)
CA (1) CA2838950C (enExample)
EA (1) EA030381B1 (enExample)
ES (1) ES2671381T3 (enExample)
IL (1) IL229902B (enExample)
SG (2) SG10201605265TA (enExample)
WO (1) WO2012174220A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン,インコーポレイテッド 慢性b型肝炎感染症のための酵母系免疫療法組成物
SG193396A1 (en) 2011-03-17 2013-10-30 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
WO2012174220A1 (en) 2011-06-14 2012-12-20 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
RU2642300C2 (ru) 2011-08-17 2018-01-24 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения
SG11201408652SA (en) 2012-06-26 2015-01-29 Biodesix Inc Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
KR20150132867A (ko) 2013-03-19 2015-11-26 글로브이뮨 척색종에 대한 효모-기반의 면역치료
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
US10799567B2 (en) * 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
EP3226973A4 (en) * 2014-12-04 2018-05-30 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR20170102002A (ko) 2015-01-09 2017-09-06 이투빅스 코포레이션 에볼라 바이러스 백신접종을 위한 방법 및 조성물
US10835496B2 (en) 2015-04-21 2020-11-17 Eiger Biopharmaceuticals, Inc. Pharmaceutical compositions comprising lonafarnib and ritonavir
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン,インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
LT3416675T (lt) * 2016-02-19 2021-06-25 Eiger Biopharmaceuticals, Inc. Hepatito delta viruso infekcijos gydymas interferonu lambda
CN107641661A (zh) * 2016-12-28 2018-01-30 成都百泰赛维生物科技有限公司 一种用于检测汉族人hdv病毒的试剂盒
CN107653342A (zh) * 2016-12-28 2018-02-02 成都百泰赛维生物科技有限公司 一种pcr法检测汉族人hdv病毒的方法
CN112543640B (zh) 2018-05-15 2025-02-14 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US20230131808A1 (en) * 2020-04-22 2023-04-27 Southlake Pharmaceuticals, Inc. Pegylated interferon tau and compositions and methods thereof
WO2024123891A1 (en) * 2022-12-07 2024-06-13 The University Of North Carolina At Chapel Hill Office Of Technology Commercialization Engineered microorganism compositions and applications thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2486400B1 (fr) 1980-07-09 1986-05-30 Univablot Medicaments a base de levures ou de leurs extraits insolubles
NZ199722A (en) 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US5310654A (en) 1985-07-31 1994-05-10 The Board Of Trustees Of The Leland Stanford Junior University Method for determining virulence of Yersinia
US5234830A (en) 1988-02-03 1993-08-10 Suntory Limited DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region
IL95019A0 (en) 1989-08-09 1991-06-10 Mycogen Corp Process for encapsulation of biologicals
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
AU4270196A (en) * 1994-10-07 1996-05-02 Lutz Gissmann Papilloma virus-like particles, fusion proteins and process for producing the same
US5858378A (en) 1996-05-02 1999-01-12 Galagen, Inc. Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen
AUPO434196A0 (en) * 1996-12-24 1997-01-23 Crown In The Right Of The Queensland Department Of Health, The An improved therapeutic
US6844171B1 (en) 1998-07-02 2005-01-18 President And Fellows Of Harvard College Oligomerization of hepatitis delta antigen
US20020044948A1 (en) 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
AU2002225681A1 (en) 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
FR2830019B1 (fr) * 2001-09-24 2005-01-07 Assist Publ Hopitaux De Paris Molecules d'acides nucleiques d'hdv, leurs fragments et leurs apllications
CN1622828A (zh) 2001-12-18 2005-06-01 基因创新有限公司 用于诊断和治疗用途的纯化的丙型肝炎病毒外被蛋白
KR101241272B1 (ko) 2002-12-16 2013-03-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 면역 요법으로서의 효모계 백신
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2006253891B2 (en) * 2005-02-25 2011-12-01 Zoetis P Llc N Protein Mutants of Porcine reproductive and respiratory syndrome virus
US20100034840A1 (en) 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
KR20140029551A (ko) 2006-02-02 2014-03-10 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신
EP2004666B1 (en) 2006-03-27 2014-09-03 Globeimmune, Inc. Ras mutation and compositions and methods related thereto
US20080138354A1 (en) * 2006-07-21 2008-06-12 City Of Hope Cytomegalovirus vaccine
EP2121013B1 (en) 2007-02-02 2014-10-15 Globeimmune, Inc. Methods for producing yeast-based vaccines
CA2681246A1 (en) 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US8728489B2 (en) 2008-09-19 2014-05-20 Globeimmune, Inc. Immunotherapy for chronic hepatitis C virus infection
WO2010065626A1 (en) 2008-12-02 2010-06-10 Globeimmune, Inc. Genotyping tools, methods and kits
ITTO20080964A1 (it) * 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
EP3320915A1 (en) 2009-04-17 2018-05-16 Globeimmune, Inc. Combination immunotherapy compositions against cancer and methods
BR112012002628B1 (pt) * 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
AU2010291985B2 (en) * 2009-09-14 2016-05-05 The Regents Of The University Of Colorado Modulation of yeast-based immunotherapy products and responses
WO2011115914A1 (en) 2010-03-14 2011-09-22 Globeimmune, Inc. Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy
WO2012019127A2 (en) 2010-08-05 2012-02-09 The Regents Of The University Of Colorado Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン,インコーポレイテッド 慢性b型肝炎感染症のための酵母系免疫療法組成物
SG193396A1 (en) 2011-03-17 2013-10-30 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
WO2012174220A1 (en) 2011-06-14 2012-12-20 Globeimmune, Inc. Yeast-based compositions and methods for the treatment or prevention of hepatitis delta virus infection
RU2642300C2 (ru) 2011-08-17 2018-01-24 Глоубиммьюн, Инк. Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения

Similar Documents

Publication Publication Date Title
Moorlag et al. Non-specific effects of BCG vaccine on viral infections
JP2016128513A5 (enExample)
Chang et al. Prevention of hepatitis B
JP2014507144A5 (ja) 慢性b型肝炎感染症のための酵母系免疫療法組成物
Paladini et al. The worldwide impact of vaccination on the control and protection of viral hepatitis B
JP2015096557A5 (enExample)
JP2019151636A5 (enExample)
JP2017515508A5 (enExample)
JP2016534034A5 (enExample)
JP2014530010A5 (enExample)
Bramwell et al. The rational design of vaccines
JP2015214545A5 (enExample)
JP2012506411A5 (enExample)
JP2010500399A5 (enExample)
JP2019531293A5 (enExample)
JP2011528897A5 (enExample)
Gerretsen et al. Development of respiratory syncytial virus (RSV) vaccines for infants
JP2010506926A5 (enExample)
JP2014519817A5 (enExample)
JP7403733B2 (ja) インフルエンザhaスプリットワクチンの製造方法
JP2016521754A5 (enExample)
JP2022514759A5 (enExample)
FI3220937T3 (fi) Pneumolysiinimutantteja ja menetelmiä niiden käyttämiseksi
Ahire et al. Immune responses induced by different vaccine platforms against coronavirus disease-19
JP2014502143A5 (enExample)